Aceragen, Inc.: restructuring charge — Aceragen lays off ~80% of staff, CFO departs; cash runway only into May 2023; FDA lifts clinical hold on ACG-801

Aceragen, Inc.

Approximately 80% of employees terminated effective April 28, 2023; expects ~$4.5M restructuring charges in Q2 2023.
CFO John Kirby departs; CEO John Taylor assumes CFO duties effective immediately.
Existing cash and equivalents fund operations only into May 2023; needs to raise additional capital.
FDA lifts clinical hold on ACG-801 for Farber disease, enabling ADVANCE study subject to financing availability.
Company warns it may need to scale back development, seek a sale, or cease operations if unable to raise capital.

item 2.05 item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

John Taylor

Chief Financial Officer

Aceragen, Inc.

Filed: May 4, 2023, 7:59 PM ET

John Taylor, the Company's Chief Executive Officer, has assumed the duties of Chief Financial Officer of the Company as of the Effective Date.

Departed

John Kirby

Chief Financial Officer

Aceragen, Inc.

Successor: John Taylor
Filed: May 4, 2023, 7:59 PM ET

John Kirby no longer serves as the Company's Chief Financial Officer or is employed by the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

John Taylor changed role as Chief Financial Officer at Aceragen, Inc..

Action: assumed duties of Chief Financial Officer
Role: Chief Financial Officer

Exact text from the filing

John Taylor, the Company's Chief Executive Officer, has assumed the duties of Chief Financial Officer of the Company as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

John Kirby departed as Chief Financial Officer at Aceragen, Inc..

Action: no longer serves
Role: Chief Financial Officer

Exact text from the filing

John Kirby no longer serves as the Company's Chief Financial Officer or is employed by the Company.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Aceragen, Inc. announced a restructuring with charges of approximately $4.5 million (approximately 80% of the Company’s employees).

Type: restructuring
Charge: approximately $4.5 million
Headcount: approximately 80% of the Company’s employees

Exact text from the filing

(the “2022 Form 10-K”). In connection with the Reduction, the Company estimates that it will incur aggregate restructuring charges in the second quarter of 2023 of approximately $4.5 million related to severance payments and other employee-related costs. The Company’s estimates are subject to a number of assumptions, and actual results may differ. The Company may

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001104659-23-055819

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.